CD4

Across TCGA pan-cancer cohorts, CD4 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CD4 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD4 expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

BRCA, ESCA, and LIHC are the cancer types where CD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.801	0.963	<.001	16	view →
ESCA	DFS	Median	II,III,IV	0.123	0.526	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.226	0.716	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	DFS	Median	IV	0.184	0.672	.006	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	All	1.000	0.609	.046	4	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CD4–BRCA (OS)

Open the BRCA breakdown →